[Clinical and experimental study on sustained release tablet of Tripterygium wilfordii in treating rheumatoid arthritis].
Adopt to the prospective, multi-center, random, single-blind, equal rank-control methods, 226 patients of rheumatoid arthritis diagnosed according to the ARA criteria, were divided into 2 groups. One hundred and fourteen patients of test group were treated with sustained release tablets of Tripterygium wilfordii (TW-SR) orally, 2 tablets, twice a day for 4 weeks, 112 patients of control group received tablets of Tripterygium wilfordii (TW) orally, 2 tablets 3 times per day for 4 weeks. Results showed that the total effective rate of the two groups were 92.11% and 90.65%, respectively (P > 0.05). The adverse reaction rate of TW-SR group was 20.18%, which was lowered than that of TW group (70.54%, P < 0.01). Results of pre-clinical pharmacologic experimental study showed that the TW-SR has obvious anti-inflammatory, analgesia and immunosuppress'ive action as the TW has, while its toxicity was less than the latter significantly.
Li
R L
RL
Honghu Institute of Rheumatic Disease, Hubei.
Liu
P L
PL
Wu
X C
XC
D000328:Adult; D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004285:Dogs; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008875:Middle Aged; D011446:Prospective Studies; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D016037:Single-Blind Method; D029757:Tripterygium
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D004365:Drugs, Chinese Herbal; D007166:Immunosuppressive Agents